Immunogenicity of GI-4000 vaccine in adjuvant consolidation therapy following definitive treatment in patients with stage I-III adenocarcinoma of the lung with G12C, G12D, or G12V KRAS mutations.

7070 Background: All patients at MSKCC with lung adenocarcinoma undergo reflex testing for EGFR and KRAS mutations at the time of surgical resection. KRAS mutations occurred in 19% of resected lung adenocarcinomas at MSKCC from 2006- 4/2009. GI-4000 is a recombinant, yeast-based vaccine (S. cerevisiae) engineered to express one of 4 mutated RAS oncoproteins… CONTINUE READING